Tradestie Institutional Equity Comparison Engine
MBIO vs ANRO โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
ANRO Overall Edge
ANRO Captures Institutional Edge (2โ1 Pillars ยท 2โ3 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Alto Neuroscience Inc. (ANRO) driven by superior Momentum & Technical, Options & Structure while MBIO counters with relative strength in Growth & Margin. Fundamentally, MBIO trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus ANRO at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, MBIO sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against ANRO sits in BREAKDOWN (8th %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
Tie
MBIO N/M vs ANRO N/M Fwd P/E
Growth & Margin Winner
MBIO
Op Margin 0.0% vs 0.0% ยท YoY +0.0% vs +0.0%
Momentum & Technical Winner
ANRO
1Y -67.4% vs +138.9% ยท 52W Pos 4% vs 61%
Options & Structure Winner
ANRO
UNCLASSIFIED (N/A IV) vs BREAKDOWN (8th %ile IV)
MBIO
NASDAQ
Mustang Bio, Inc.
Pharmaceutical Preparations
$0.39
-6.34% 1D
Market Cap
$3.2M
1M Return
+4.86%
1Y Return
-67.38%
Forward P/E
N/M
Unified AI Score
42.9 / 100
HOLD
Tech 40.0
Fund 49.0
Flow 50.0
Mom 70.0
ANRO
NYSE
Alto Neuroscience Inc.
Pharmaceutical Preparations
$27.12
-8.19% 1D
Market Cap
$1.2B
1M Return
+23.61%
1Y Return
+138.94%
Forward P/E
N/M
Unified AI Score
30.5 / 100
SELL
Tech 5.0
Fund 32.0
Flow 65.0
Mom 40.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
MBIO -67.38%
ANRO +138.94%
Spread: +206.32 pp (ANRO Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
MBIO TTM Op. Margin: 0.0%
ANRO TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on MBIO vs ANRO. Trailing 12-month operating profitability (MBIO 0.0% vs ANRO 0.0%) and valuation multiples (MBIO N/M vs ANRO N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | MBIO | ANRO | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $3.2M | $1.2B | Larger Scale | ANRO |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | +0.0% | +0.0% | Higher Growth | Tie |
| Operating Margin (TTM) Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Net Profit Margin Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | -43.1% | -46.7% | Higher ROE | MBIO |
| 52-Week Range Position Momentum | 4% ($0โ$1) | 61% ($11โ$37) | Stronger Trend | ANRO |
| Beta / 30D Volatility Risk Regime | 0.66ฮฒ ยท 86% Vol | 1.95ฮฒ ยท 90% Vol | Lower Realized Risk | MBIO |
| Unified Institutional Score Composite Signal | 42.9 / 100 (HOLD) | 30.5 / 100 (SELL) | Higher Composite | MBIO |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full MBIO vs ANRO Buy Guide
MBIO
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
ANRO
BREAKDOWN
57d in phase ยท OBV ACCUMULATION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
8th %ile
IV Regime
Compressed (<25th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither MBIO nor ANRO registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.